Carebot

AI-based recommender systems for physicians, improving efficiency and accuracy of medical imaging diagnostics.

An AI-based tool to detect and evaluate prostate cancer on histopathology images. The target market is healthcare facilities, laboratories and clinical institutions involved in the diagnosis and treatment of prostate cancer. The company has experience in certifying AI-enabled medical devices and the ability to integrate its technology into existing image processing systems. The business model includes two options: royalties and strategic partnerships. The company has the resources to fund the development of the solution and bring it to market. The goal is to first implement the product in the domestic market and then expand to international markets.

Unique selling points:

• Automatic detection of prostate cancer using AI, providing accuracy and reliability in diagnosis.
• The ability to reduce error rates, increase the quality of diagnoses and improve outcomes for patients.
• Partnerships with leading hospitals and PACS providers in the Czech Republic.
• Contribution to faster detection and diagnosis through automatic analysis of large amounts of data.
• Effective reduction of variability in the evaluation and human error in the evaluation of histopathological samples, which improves the quality and efficiency of diagnosis.

Incubation